Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abiomed, Inc. stock logo
ABMD
Abiomed
$381.02
$380.55
$219.85
$381.99
$17.18B1.4611,028 shs258 shs
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$7.95
$7.36
$6.33
$8.38
$17.77B1.0740,773 shs10,744 shs
Insulet Co. stock logo
PODD
Insulet
$181.42
+2.4%
$172.93
$125.82
$298.95
$12.71B1.15898,214 shs675,329 shs
ResMed Inc. stock logo
RMD
ResMed
$207.39
+0.5%
$202.04
$132.24
$229.97
$30.47B0.691.03 million shs1.77 million shs
Teleflex Incorporated stock logo
TFX
Teleflex
$214.93
+2.8%
$211.38
$177.63
$262.97
$10.12B1.16346,717 shs623,450 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abiomed, Inc. stock logo
ABMD
Abiomed
0.00%0.00%0.00%0.00%0.00%
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
0.00%+1.33%+2.90%+18.55%+12.99%
Insulet Co. stock logo
PODD
Insulet
0.00%-1.60%+1.58%+5.58%-36.95%
ResMed Inc. stock logo
RMD
ResMed
0.00%-3.25%-4.91%+14.18%-6.49%
Teleflex Incorporated stock logo
TFX
Teleflex
0.00%+1.32%+2.99%-7.04%-11.59%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abiomed, Inc. stock logo
ABMD
Abiomed
N/AN/AN/AN/AN/AN/AN/AN/A
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/AN/AN/AN/AN/AN/AN/AN/A
Insulet Co. stock logo
PODD
Insulet
4.9101 of 5 stars
4.41.00.04.93.90.83.1
ResMed Inc. stock logo
RMD
ResMed
4.5925 of 5 stars
2.41.03.34.53.91.72.5
Teleflex Incorporated stock logo
TFX
Teleflex
4.502 of 5 stars
2.33.01.73.92.82.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abiomed, Inc. stock logo
ABMD
Abiomed
N/AN/AN/AN/A
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
2.50
Moderate BuyN/AN/A
Insulet Co. stock logo
PODD
Insulet
2.83
Moderate Buy$239.1831.84% Upside
ResMed Inc. stock logo
RMD
ResMed
2.70
Moderate Buy$202.80-2.21% Downside
Teleflex Incorporated stock logo
TFX
Teleflex
2.63
Moderate Buy$257.2919.71% Upside

Current Analyst Ratings

Latest TFX, ABMD, PODD, RMD, and FSNUY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/30/2024
Insulet Co. stock logo
PODD
Insulet
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$235.00
5/13/2024
Insulet Co. stock logo
PODD
Insulet
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$213.00 ➝ $200.00
5/10/2024
Insulet Co. stock logo
PODD
Insulet
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$226.00 ➝ $234.00
5/10/2024
Insulet Co. stock logo
PODD
Insulet
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$218.00 ➝ $213.00
5/10/2024
Insulet Co. stock logo
PODD
Insulet
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$255.00 ➝ $260.00
5/7/2024
Insulet Co. stock logo
PODD
Insulet
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$200.00
5/3/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$240.00 ➝ $219.00
5/3/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$205.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$187.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$227.00 ➝ $238.00
(Data available from 6/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abiomed, Inc. stock logo
ABMD
Abiomed
$1.03B16.65$5.09 per share74.88$33.03 per share11.54
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$24.01B0.74$2.20 per share3.62$15.07 per share0.53
Insulet Co. stock logo
PODD
Insulet
$1.70B7.49$3.89 per share46.69$10.49 per share17.29
ResMed Inc. stock logo
RMD
ResMed
$4.22B7.21$7.85 per share26.42$28.11 per share7.38
Teleflex Incorporated stock logo
TFX
Teleflex
$2.97B3.40$19.36 per share11.10$94.49 per share2.27

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abiomed, Inc. stock logo
ABMD
Abiomed
$136.51M$5.8265.4769.783.3324.84%14.77%13.32%N/A
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
-$639.61M$0.1172.308.46N/A0.71%4.88%2.02%N/A
Insulet Co. stock logo
PODD
Insulet
$206.30M$3.3054.9748.253.1913.14%34.06%9.08%8/13/2024 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$897.56M$6.5131.8623.782.0320.91%24.43%15.70%8/1/2024 (Estimated)
Teleflex Incorporated stock logo
TFX
Teleflex
$356.33M$6.2334.5014.172.029.82%14.78%8.79%8/1/2024 (Estimated)

Latest TFX, ABMD, PODD, RMD, and FSNUY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024Q1 2024
Insulet Co. stock logo
PODD
Insulet
$0.39$0.73+$0.34$0.73$424.05 million$441.70 million    
5/2/2024Q1 2024
Teleflex Incorporated stock logo
TFX
Teleflex
$3.07$3.21+$0.14$6.10$726.85 million$737.80 million      
4/25/2024Q3 24
ResMed Inc. stock logo
RMD
ResMed
$1.91$2.13+$0.22$2.22$1.17 billion$1.20 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abiomed, Inc. stock logo
ABMD
Abiomed
N/AN/AN/AN/AN/A
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
$0.162.01%N/A145.45%N/A
Insulet Co. stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$1.920.93%+5.66%29.49%12 Years
Teleflex Incorporated stock logo
TFX
Teleflex
$1.360.63%N/A21.83%N/A

Latest TFX, ABMD, PODD, RMD, and FSNUY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Quarterly$0.340.68%5/14/20245/15/20246/14/2024
4/25/2024
ResMed Inc. stock logo
RMD
ResMed
Quarterly$0.480.88%5/8/20245/9/20246/13/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abiomed, Inc. stock logo
ABMD
Abiomed
N/A
7.93
7.17
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
0.36
1.54
1.44
Insulet Co. stock logo
PODD
Insulet
1.72
3.74
2.75
ResMed Inc. stock logo
RMD
ResMed
0.22
3.04
1.97
Teleflex Incorporated stock logo
TFX
Teleflex
0.37
2.51
1.41

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
94.48%
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/A
Insulet Co. stock logo
PODD
Insulet
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%

Insider Ownership

CompanyInsider Ownership
Abiomed, Inc. stock logo
ABMD
Abiomed
2.50%
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
N/A
Insulet Co. stock logo
PODD
Insulet
0.47%
ResMed Inc. stock logo
RMD
ResMed
1.21%
Teleflex Incorporated stock logo
TFX
Teleflex
1.43%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Abiomed, Inc. stock logo
ABMD
Abiomed
2,00345.09 million43.96 millionOptionable
Fresenius SE & Co. KGaA stock logo
FSNUY
Fresenius SE & Co. KGaA
316,9202.23 billionN/ANot Optionable
Insulet Co. stock logo
PODD
Insulet
3,00070.04 million69.71 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
10,140146.91 million145.13 millionOptionable
Teleflex Incorporated stock logo
TFX
Teleflex
14,50047.10 million46.43 millionOptionable

FSNUY, PODD, TFX, ABMD, and RMD Headlines

Recent News About These Companies

Teleflex (NYSE:TFX) Sees Unusually-High Trading Volume
Teleflex (NYSE:TFX) Shares Gap Down to $219.79

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Abiomed logo

Abiomed

NASDAQ:ABMD
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA

OTCMKTS:FSNUY
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Insulet logo

Insulet

NASDAQ:PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
ResMed logo

ResMed

NYSE:RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
Teleflex logo

Teleflex

NYSE:TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.